Patients
Between October 1992 and December 1993, 35 cirrhotic patients and 29 CAH patients with hepatitis C were enrolled in this study. The diagnoses were based on the result liver function tests, HCV-antibody positivity and histopathological findings in the liver before IFN treatment. According to Pugh's modification of the Child-Turcotte index15), six cirrhotic patients were classified into Child B and the other cirrhotic patients were categorized as Child A. All patients lacked hepatitis B surface antigen (HBsAg) as determined by enzyme immunoassay (EIA; Mizuho Medy Co., Ltd., Tosu, Japan). Patients with ascites, hepatic encephalopathy, and other types of chronic liver disease were excluded. Written informed consent was obtained from all patients. Methods HCV Antibody Anti-HCV was detected by passive hemagglutination using 2nd generation HCV antibody (Abbott HCV PHA 2nd Generation, Dainabot Co., Ltd., Tokyo, Japan).
HCV RNA Serum HCV RNA was amplified by reverse transcription-"nested" polymerase chain reaction (RT-PCR) using the method described by Okamoto et al16). The cDNA was subjected to PCR amplification using a set of 5'-non coding region primers, 5'-GGCGACACTCCACCATGAATCACT-3' (sense primer), and 5'-CACGAATTCAGTCTTCTTTGTCGCGCACACCCAA-3' (antisense primer) for the first for the first round PCR, and 5'-ATAGGATCCACTCCCCTGAGGAACTACTGTC-3' sense, 5'-ATGAATTCATGGTGCACGGTCTACGAGACCTCCCG-3' (antisen seprimer) for the second round PCR17). The PCR products were analyzed by agarose gel electrophoresis and ethidium bromide staining.
Serum HCV RNA level Serum HCV RNA levels were determined by competitive reverse transcription-polymerase chain reaction (RT-PCR) according to the method described by Kato et al18).
Genotyping of HCV HCV genotyping was done using a modification of the method of Okamoto et al.19) . The second PCR products were analyzed by electrophoresis in 3% agarose gel, stained with ethidium bromide, and examined under UV light. HCVs were then classified into four types: Type I: 57 pb, Type II: 144 bp, Type III: 174 bp, Type IV: 123 bp DNA fragments and mixed type.
Interferon treatment Human lymphoblastoid interferon (natural IFN-cr; Sumitomo Pharmaceutical Co., Ltd, Tokyo, Japan) was used. The Cirrhotic patients received 3 or 6 million units (MU) intramuscularly daily for 1 or 2 weeks and then three times a week for 22 or 23 weeks for a total of 24 weeks of treatment. Before treatment, the patients were randomly assigned to two groups based on the total dose of interferon to be given. The dose of interferon was reduced or the drug was discontinued when severe side effects occurred. The patients in the low-dose group (LD-group) received 168-288 MU, and those in the high-dose group (HD-group) received 432-468 MU. The patients with CAH received 6 MU daily for 2 weeks and then three times a week for 14 or 16 weeks. The total dose in these patients ranged from 336-372 MU. All of the patients were monitored for at least 6 months following treatment. Complete responders (CRs) were defined as patients whose serum alanine aminotransferase (ALT) level remained normal and in whom no serum HCV RNA was detected for at least 6 months after the end of treatment. Non-responders (N Rs) were defined as patients whose HCV RNA reappeared within 6 months after the end of treatment, even though their ALT level fell to within the normal range. 
